Future aspects of somatostatin-receptor-mediated therapy

Neuroendocrinology

Volumn 80, Issue SUPPL. 1, 2004, Pages 57-61

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytotoxic coupled somatostatin analogue; SOM230; Ultra high dose treatment

Indexed keywords

ANGIOPEPTIN; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; OCTREOTIDE; PASIREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; VAPREOTIDE;

ACROMEGALY; BINDING AFFINITY; CARCINOID; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEVER; GALLSTONE; GASTROINTESTINAL TUMOR; HUMAN; IC 50; MOLECULAR CLONING; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL;

ANTIGENS, CD31; BINDING SITES; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 6044276093     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080743     Document Type: Conference Paper

References (12)

1. Brazeau P, Vale W, Burgus R, et al: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
2. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Somatostatin analogs: Future directions. Metabolism 1996;45:104-106.
3. Pless J, Bauer W, Briner U, et al: Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl 1986;119:54-64.
4. Patel YC, Greenwood MT, Panetta R, et al: The somatostatin receptor family. Life Sci 1995;57:1249-1265.
5. Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-442.
6. Reubi JC, Laissue J, Waser B, et al: Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994;733:122-137.
7. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Ann Oncol 1997;8:1041-1044.
8. Faiss S, Rath U, Mansmann U, et al: Ultrahigh-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999;60:469-476.
9. Lokich J: Carcinoid tumor regression with high-dose octreotide acetate: A patient report. Am J Clin Oncol 1998;21:246-247.
10. Weckbecker G, Briner U, Lewis I, Bruns C: SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143:4123-4130.
11. Bruns C, Lewis I, Briner U, et al: SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-716.
12. Szepeshazi K, Schally AV, Nagy A, et al: Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003;98:1401-1410.